Dr. Cuss led the development of nivolumab and other important products, having spent more than 30 years in the pharmaceutical industry. Trained as a medical doctor, he has a great sense for translation and clinical trial design. A true physician-scientist, he was head of Research at BMS for nearly a decade. Dr. Cuss also serves on the boards of Glympse Bio, Rubius Therapeutics, and Novo Holdings.